Natural iminosugar derivatives of 1-deoxynojirimycin inhibit glycosylation of hepatitis viral envelope proteins

Journal of Microbiology

Volumn 45, Issue 5, 2007, Pages 431-440

  Jacob, James R ^a   Mansfield, Keith ^b   You, Jung Eun ^c   Tennant, Bud C ^a   Kim, Young Ho ^c  

^a Animal Health Diagnostic Center   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Suwon University   (South Korea)

Author keywords

1 deoxynojirimycin; Glycosylation inhibition; Hepatitis virus; Iminosugar; Silkworm

Indexed keywords

1 DEOXYNOJIRIMYCIN; ANTIVIRUS AGENT; CARBOHYDRATE; DRUG DERIVATIVE; IMINO ACID; TISSUE EXTRACT; VIRUS ENVELOPE PROTEIN;

ANIMAL; ARTICLE; CHEMISTRY; CLASSIFICATION; CYTOLOGY; DRUG EFFECT; FLAVIVIRUS; GLYCOSYLATION; HEPATITIS VIRUS; ISOLATION AND PURIFICATION; LIVER CELL; MARMOSET; METABOLISM; SILKWORM;

1-DEOXYNOJIRIMYCIN; ANIMALS; ANTIVIRAL AGENTS; BOMBYX; CALLITHRIX; CARBOHYDRATES; FLAVIVIRIDAE; GLYCOSYLATION; HEPATITIS VIRUSES; HEPATOCYTES; IMINO ACIDS; TISSUE EXTRACTS; VIRAL ENVELOPE PROTEINS;

ANIMALIA; BOMBYX MORI; BOVINE VIRAL DIARRHEA VIRUS 1; FLAVIVIRIDAE; FLAVIVIRUS; HEPADNAVIRIDAE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS GB VIRUS B; MORUS (PLANT); MORUS ALBA; MORUS(ANGIOSPERM); WOODCHUCK HEPATITIS VIRUS;

EID: 35648940330     PISSN: 12258873     EISSN: 12258873     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Asano, N. 2003. Glycosidase inhibitors: update and perspectives on practical use. Glycobiology 13, 93R-104R.
2. Asano, N., K. Oseki, H. Kizu, and K. Matsui. 1994. Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J. Med. Chem. 37, 3701-3706.
3. Asano, N., K. Oseki, E. Tomioka, H. Kizu, and K. Matsui. 1994. N-containing sugars from Moms alba and their glycosidase inhibitory activities. Carbohydr. Res. 259, 243-255.
4. Asano, N., T. Yamashita, K. Yasuda, K. Ikeda, H. Kizu, Y. Kameda, A. Kato, R.J. Nash, H.S. Lee, and K.S. Ryu. 2001. Polyhy-droxylated alkaloids isolated from Mulberry trees (Morus alba L.) and silkworms (Bombyx mori L). J. Agric. Food Chem. 49, 4208-4213.
5. Beames, B., D. Chavez, B. Guerra, L. Notvall, K.M. Brasky, and R.E. Lanford. 2000. Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus. J. Virol. 74, 11764-11772.
6. Block, T.M., X. Lu, A.S. Mehta, B.S. Blumberg, B.C. Tennant, M. Ebling, B. Korba, D.M. Lansky, G.S. Jacob, and R.A. Dwek. 1998. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nature Med. 4, 610-614.
7. Block, T.M., X. Lu, F.M. Platt, G.R. Foster, W.H. Gerlich, B.S. Blumber, and R.A. Dwek. 1994. Secretion of hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. USA 91, 2235-2239.
8. Branza-Nichita, N., D. Durantel, S. Carrouee-Durantel, R.A. Dwek, and N. Zitzmann. 2001. Antiviral effects of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers. J. Virol. 75, 3527-3536.
9. Cavalletto, L., L. Chemello, C. Donada, P. Casarin, F. Belussi, E. Bernardinello, F. Marino, P. Pontisso, A. Gatta, and A. Alberti. 2000. The pattern of response to interferon alpha predicts sustained response to a 6-month alpha-INF and ribavirin retreatment for chronic hepatitis C. J. Hepatol. 33, 128-134.
10. Chisari, F.V. and C. Ferrari. 1997. Viral hepatitis, p. 745-778. In N. Nathanson (ed.), Viral pathogenesis. Lippincott-Raven Publishers, Philadelphia, PA, USA.
11. Chou, T.C. and P. Talalay. 1984. Quantitative Analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Reg. 22, 27-55.
12. Corapi, W.V, R.O. Donis, and E.J. Dubovi. 1990. Characterization of a panel of monoclonal antibodies and their use in the study of the antigenic diversity of bovine viral diarrhea virus. Am. J. Vet. Res. 51, 1388-1394.
13. Crespo, J., J.L. Lozano, B. Carte, B. De Las Heras, F. De La Cruz, and F. Pons-Romero. 1997. Viral replication in patients with concomitant hepatitis B and C virus infections. Eur. J. Clin. Infect. Dis. 16, 445-451.
14. Di Bisceglie, A.M. and B.R. Bacon. 1999. The unmet challenges of hepatitis C. Scientific American 281, 80-85.
15. Dobrinski, I., J.R. Jacob, B.C. Tennant, and B. Ball. 1999. Generation of an equine oviductal epithelial cell line for the study of sperm-oviduct interaction. Theriogenology 52, 875-885.
16. Durantel, D., N. Branza-Nichita, S. Carrouee-Durantel, T.D. Butters, R.A. Dwek, and N. Zitzmann. 2001. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J. Virol. 75, 8987-8998.
17. Hoofnagle, J.H. and A.M. Di Bisceglie. 1997. The treatment of chronic viral hepatitis. New Engl J. Med. 336, 337-356.
18. Jacob, G.S. 1995. Gylcosylation inhibitors in biology and medicine. Curr. Opin. Struct. Bool. 5, 605-611.
19. Jacob, J.R., R.H. Liu, C. Roneker, F. Noronha, J.H. Hotchkiss, and B.C. Tennant. 1994. Characterization and immortalization of woodchuck hepatocytes isolated from normal and hepadna-virus infected woodchucks (Marmota monax). Exp. Cell Res. 212, 42-48.
20. Jacob, J.R., I. Toshkov, B.E. Korba, P.J. Cote, W. DeLaney, J.L. Gerin, and B.C. Tennant. 2004. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antiviral Res. In press.
21. Jarvis, B. and D. Faulds. 1999. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 58, 101-141.
22. Jassim, S.A.A. and M.A. Naji. 2003. Novel antiviral agents: a medicinal plant perspective. J. Appl Micro. 95, 412-427.
23. Jen, J., M. Laughlin, C. Chung, S. Heft, M.B. Affrime, S.K. Gupta, P. Glue, and G. Hajian. 2002. Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic-pharmaco-dynamic models. Clin. Pharmacol Therapeutics 72, 349-361.
24. Joubert, P.H., C.P. Venter, H.F. Joubert, and I. Hillebrand. 1985. The effect of 1-deoxynojirimycin derivative on post-pradial blood glucose and insulin levels in healthy black and white volunteers. Eur. J. Clin. Pharmacol. 28, 705-708.
25. Khakoo, S., P.G. Glue, L. Grellier, B. Wells, A. Bell, C. Dash, I. Murray-Lyon, D. Lypnyj, B. Flannery, K. Walters, and G.M. Dusheiko. 1998. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br. J. Clin. Pharmacol 46, 563-570.
26. Kimura, M., F.J. Chen, N. Nakashima, I. Kimura, N. Asano, and S. Koya. 1995. Antihyperglycemic effects of N-containing sugars derived from Mulberry leaves in streptozocin-induced diabetic mice. J. Trad. Med 12, 214-219.
27. Korba, B.E. and J.L. Gerin. 1992. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 19, 55-70.
28. Lanford, R.E., D. Chavez, B. Guerra, J.Y.N. Lau, Z. Hong, K.M. Brasky, and B. Beames. 2001. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 75, 8074-8081.
29. Liang, TJ. 1999. Complementary and alternative medicine: The roots of healing. Gastroenterology 117, 1041.
30. Liaw, Y.F. 2001. Concurrent hepatitis B and C virus infection: is hepatitis C virus stronger? J. Gastroenterol Hepatol. 16, 597-598.
31. Liu, J., L. Kjaergard, and C. Glund. 2002. Misuse of randomization: a review of Chinese randomized trials of herbal medicines for chronic hepatitis B. Amer. J. Chinese Med. 30, 173-176.
32. Look, M.P., A. Gerard, G.S. Rao, T. Sudhop, H.P. Fischer, T. Sauerbruch, and U. Spengler. 1999. Interferon/antioxidant combination therapy for chronic hepatitis C-a controlled pilot trial. Antiviral Res. 43, 113-122.
33. Lu, X., A. Mehta, R. Dwek, T. Butters, and T. Block. 1995. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. Virol. 213, 660-665.
34. Martin, K.W. and E. Ernest. 2003. Antiviral agents from plants and herbs; a systemic review. Antivir. Ther. 8, 77-90.
35. McHutchison, J.G., S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, Z.D. Goodman, M.H. Ling, S. Cort, and J.K. Albrecht. 1998. Interferon alpha 2a alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England J. Med. 339, 1485-1492.
36. Mehta, A., B. Conyers, D.L.J. Tyrrell, K.A. Walters, G.A. Tipples, R. Dwek, and T.M. Block. 2002. Structure-activity relationship of a new class of anti-hepatitis B virus agents. Antimicro. Agents Chemo. 46, 4004-4008.
37. Ouzounzov, S., A.D. Menta, T.M. Block, and R. Jordan. 2002. The combination of interferon α-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy. Antiviral Res. 55, 425-435.
38. Pestka, S. 1986. Interferon Standards and general abbreviations. Meth. Enzymol. 119, 14-23.
39. Schuppan, D., J.D. Jia, B. Brinhaus, and E.G. Hann, 1999. Herbai products for liver diseases: A therapeutic challenge for the new millennium. Hepatology 30, 1099-1104.
40. Schvarcz, R., Z.B. Yun, A. Sonnerborg, and O. Weiland. 1995. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J. Med. Virol. 46, 43-47.
41. Seeff, L.B., K.L. Lindsay, B.R. Bacon, T.F Kresina, and J.H. Hoofnagle. 2001. Complementary and alternative medicine in chronic liver disease. Hepatology 34, 595-603.
42. Stephensen, C.B., J.R. Jacob, R.J. Montali, R.J. Montali, E.D. Armes, M.J. Buchmeler, E. Muchmore, K.V. Holmes, and R.E. Lanford. 1991. Isolation of an arenavirus from a marmoset with callitrichid hepatitis and its serologic association with disease. J. Virol. 65, 3995-4000.
43. Strader, D.B. and H.J. Zimmerman. 2000. Complementary and alternative medicine in Hepatitis C, p. 363-386. In T.J. Liang and J.H. Hoofnagle (ed.), Biomedical Research Reports; Hepatitis C. Academic Press, New York, NY, USA.
44. Tolle, T.K., D. Glebe, M. Linder, D. Linder, S. Schmitt, R. Geyer, and W.H. Gerlich. 1998. Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. J. Virol. 72, 9978-9985.
45. Tsiang, M., J.F Roonex, J.J. Toole, and G.S. Gibbs. 1999. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 29, 1863-1869.
46. Vilcek, J. and G.C. Sen. 1996. Interferons and other cytokines, p. 375-399. In B.N. Fields, D.M. Knipe, and P.M. Howley (ed.), Fields Virology. Lippincott-Raven Publishers, Philadelphia, PA, USA
47. Wu, S.R, C.J. Lee, C.L. Liao, R.A. Dwek, N. Zitzmann, and Y.L. Lin. 2002. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 67, 3596-3604.
48. Zitzmann, N., A.S. Mehta, S. Carrouee, T.D. Butters, F.M. Piatt, J. McCauley, B.S. Blumberg, R.A. Dwek, and TM. Block. 1999. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl. Acad. Sci. USA 96, 11878-11882.